ClinicalTrials.gg
CompletedNCT04638660Updated Oct 30, 2026Results posted

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances

A Phase 3 interventional study of Phentolamine Ophthalmic Solution 0.75% and Phentolamine Ophthalmic Solution Vehicle (Placebo) in Dim Light Vision Disturbances, sponsored by Opus Genetics, Inc. Completed at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Opus Genetics, Inc · Phase 3, Interventional, and Treatment

Updated Oct 30, 2026Sponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objectives of this study are:

  • To evaluate the efficacy of Nyxol to improve mesopic low contrast visual acuity (mLCVA) in subjects with Dim Light Vision Disturbances (DLD)
  • To evaluate efficacy of Nyxol to improve visual performance
  • To evaluate the safety of Nyxol
Read the detailed description

Placebo-controlled, double-masked, multiple-dose, Phase 3 study in approximately 160 randomized subjects with DLD (approximately 136 that are evaluable for efficacy), evaluating safety and efficacy of Nyxol in subjects with DLD following administration of Nyxol once daily (QD) at or near bedtime (at 8PM to 10PM) in both eyes (OU) for 14 days.

Following the successful completion of screening, each subject will be stratified by iris color (light/dark irides) and will then be randomized to treatment (masked) 1:1, Nyxol or placebo (vehicle).

Treatment (Nyxol or placebo) will be administered in both eyes (OU) by the subjects at or near bedtime each day.

At the first visit subjects will be screened for study eligibility.

Treatment visits will occur 2 times: Day 8 (+1 day)/Visit 2 and Day 15 (+1 day)/Visit 3. mLCVA evaluations shall be performed on each of these days.

A follow-up visit (Visit 4) phone call will occur 1 to 3 days after Visit 3.

At select sites OPD Scan measurements will be made using wavefront abhermettry.

02

Conditions studied

  • Dim Light Vision Disturbances

Keywords

  • Nyxol, Night Vision Disturbances, Glare, Halos, Starbursts
03

In context

Lead sponsor

Opus Genetics, Inc is the lead sponsor of 17 studies on the registry; 4 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females ≥ 18 years of age
  2. Subject-reported DLD (likely subjects with a history of multifocal IOLs, post-laser-assisted in situ keratomileusis [LASIK], corneal scars, and keratoconus)
  3. Ability to comply with all protocol-mandated procedures independently and to attend all
  4. Otherwise healthy and well-controlled subjects
  5. Able and willing to give written consent to participate in this study
  6. Able to self-administer study medication
  7. PD ≥ 6 mm under mesopic conditions (prior to illumination) in at least one eye
  8. ≤ 20 (20/100 Snellen or worse) ETDRS letters in mLCVA score
  9. ≥10 ETDRS letters ( ≥2 lines) improvement in mLCVA in at least one eye during illumination of the contralateral eye with a BAT system on low setting

Exclusion criteria

Exclusion Criteria:

Ophthalmic:

  1. Prior history of dry eye diagnosis, taking prescription drops for dry eye, or taking artificial tear drops occasionally for dry eye
  2. Prior history of fluctuating vision
  3. ocular disease as deemed by the Investigator that might interfere with the study
  4. Known to any topical alpha-adrenoceptor antagonists
  5. Known allergy or to any component of the vehicle formulation
  6. History of cauterization of the punctum or punctal plug (silicone or collagen) insertion or removal
  7. Ocular trauma, ocular surgery (e.g., IOLs) or laser procedure (e.g., LASIK, photorefractive keratectomy [PRK]) within 6 months prior to screening
  8. Use of any topical prescription or over-the-counter (OTC) ophthalmic medications of any kind within 7 days of screening
  9. Recent or current evidence of ocular infection or inflammation in either eye. Subjects must be symptom free for at least 7 days.
  10. History of diabetic retinopathy, diabetic macular edema, or dry or wet macular degeneration
  11. History of any traumatic (surgical or nonsurgical) or nontraumatic condition affecting the pupil or iris
  12. Unwilling or unable to discontinue use of contact lenses at screening until study completion, except for keratoconus subjects who may wear contacts up to 24 hours prior to their scheduled visits

Systemic:

  1. Known hypersensitivity or contraindication to alpha- and/or beta-adrenoceptor antagonists
  2. Clinically significant systemic disease that might interfere with the study
  3. Initiation of treatment with or any changes to the current dosage, drug, or regimen of any systemic adrenergic or cholinergic drugs within 7 days prior to screening or during the study
  4. Participation in any study within 30 days prior to screening and during the conduct of the study
  5. Females of who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of
  6. Resting HR outside the specified range (50-110 beats per minute)
  7. Hypertension with resting diastolic BP > 105 mmHg or systolic BP > 160 mmHg
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    Phentolamine Ophthalmic Solution 0.75%

    One drop in both eyes at or near bedtime (8PM to 10PM)

    Drug: Phentolamine Ophthalmic Solution 0.75%

  • Placebo comparator
    Phentolamine Ophthalmic Solution Vehicle

    One drop in both eyes at or near bedtime (8PM to 10PM)

    Drug: Phentolamine Ophthalmic Solution Vehicle (Placebo)

Interventions

  • 0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist

    Also known as: Nyxol, Nyxol®

  • DrugPhentolamine Ophthalmic Solution Vehicle (Placebo)

    Topical sterile ophthalmic solution

06

What researchers measure

Primary outcomes

  1. Percent of Subjects With 3 Lines mLCVA Improvement in Study Eye

    Percent of subjects with ≥ 15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (≥3 lines) of improvement in the study eye compared to baseline in monocular mLCVA at Day 8

    Time frame: 8 days

Secondary outcomes

  1. Percent of Subjects With mLCVA Improvement in Study Eye

    Percent of subjects with ≥ 5, ≥ 10, and ≥ 15 ETDRS letters (≥ 1, ≥ 2, and ≥ 3 lines, respectively) improvement compared to baseline in mLCVA at Day 8 (excluding the primary endpoint)

    Time frame: up to 15 days

  2. Percent of Subjects With Photopic Low Contrast Visual Acuity (pLCVA) and mHCVA Improvement in Study Eye

    Percent of subjects with ≥ 5, ≥ 10, and ≥ 15 ETDRS letters (≥ 1, ≥ 2, and ≥ 3 lines, respectively) improvement compared to baseline in pLCVA and mHCVA at Day 8 and Day 15

    Time frame: up to 15 days

  3. Change From Baseline in Study Eye Mesopic Pupil Diameter (PD)

    Change from baseline in study eye mesopic PD

    Time frame: up to 15 days

  4. Percent Change From Baseline in Study Eye Mesopic Pupil Diameter (PD)

    Percent change from baseline in study eye mesopic PD

    Time frame: up to 15 days

07

Results

Posted Aug 9, 2023

Participant flow

Participant flow — Overall Study
MilestonePhentolamine Ophthalmic Solution 0.75%Phentolamine Ophthalmic Solution Vehicle
Started7173
Completed6873
Not completed30
Withdrew: Withdrawal by subject20
Withdrew: Lost to follow-up10

Outcome measures

PrimaryPercent of Subjects With 3 Lines mLCVA Improvement in Study Eye

Percent of subjects with ≥ 15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (≥3 lines) of improvement in the study eye compared to baseline in monocular mLCVA at Day 8

Time frame:
8 days
Reported as:
Count of participants · Participants
Percent of Subjects With 3 Lines mLCVA Improvement in Study Eye
ParticipantsPhentolamine Ophthalmic Solution 0.75%Phentolamine Ophthalmic Solution Vehicle
Percent of Subjects With 3 Lines mLCVA Improvement in Study Eye92
SecondaryPercent of Subjects With mLCVA Improvement in Study Eye

Percent of subjects with ≥ 5, ≥ 10, and ≥ 15 ETDRS letters (≥ 1, ≥ 2, and ≥ 3 lines, respectively) improvement compared to baseline in mLCVA at Day 8 (excluding the primary endpoint)

Time frame:
up to 15 days
Reported as:
Count of participants · Participants
Percent of Subjects With mLCVA Improvement in Study Eye
ParticipantsPhentolamine Ophthalmic Solution 0.75%Phentolamine Ophthalmic Solution Vehicle
Day 8 — >= 15 letters92
Day 8 — 10-14 letters2014
Day 8 — 5-9 letters2229
Day 8 — Less than 51928
Day 15 — >= 15 letters142
Day 15 — 10-14 letters1615
Day 15 — 5-9 letters2839
Day 15 — Less than 51017
SecondaryPercent of Subjects With Photopic Low Contrast Visual Acuity (pLCVA) and mHCVA Improvement in Study Eye

Percent of subjects with ≥ 5, ≥ 10, and ≥ 15 ETDRS letters (≥ 1, ≥ 2, and ≥ 3 lines, respectively) improvement compared to baseline in pLCVA and mHCVA at Day 8 and Day 15

Time frame:
up to 15 days
Reported as:
Count of participants · Participants
Percent of Subjects With Photopic Low Contrast Visual Acuity (pLCVA) and mHCVA Improvement in Study Eye
ParticipantsPhentolamine Ophthalmic Solution 0.75%Phentolamine Ophthalmic Solution Vehicle
pLVCA Day 8 — >= 15 letters30
pLVCA Day 8 — 10-14 letters129
pLVCA Day 8 — 5-9 letters2411
pLVCA Day 8 — Less than 5 letters2953
pLVCA Day 15 — >= 15 letters71
pLVCA Day 15 — 10-14 letters124
pLVCA Day 15 — 5-9 letters2220
pLVCA Day 15 — Less than 5 letters2346
mHCVA Day 8 — >= 15 letters23
mHCVA Day 8 — 10-14 letters53
mHCVA Day 8 — 5-9 letters1611
mHCVA Day 8 — Less than 5 letters4556
mHCVA Day 15 — >= 15 letters35
mHCVA Day 15 — 10-14 letters81
mHCVA Day 15 — 5-9 letters1914
mHCVA Day 15 — Less than 5 letters3451
SecondaryChange From Baseline in Study Eye Mesopic Pupil Diameter (PD)

Change from baseline in study eye mesopic PD

Time frame:
up to 15 days
Reported as:
Mean · millimeters
Change From Baseline in Study Eye Mesopic Pupil Diameter (PD)
millimetersPhentolamine Ophthalmic Solution 0.75%Phentolamine Ophthalmic Solution Vehicle
8 Days, Change from Baseline-1.081 ± 0.6931-0.130 ± 0.5608
15 Days, Change from Baseline-1.083 ± 0.6556-0.121 ± 0.4673
SecondaryPercent Change From Baseline in Study Eye Mesopic Pupil Diameter (PD)

Percent change from baseline in study eye mesopic PD

Time frame:
up to 15 days
Reported as:
Mean · percentage of change
Percent Change From Baseline in Study Eye Mesopic Pupil Diameter (PD)
percentage of changePhentolamine Ophthalmic Solution 0.75%Phentolamine Ophthalmic Solution Vehicle
8 Days, Percent Change from Baseline-17.98 ± 11.542-2.09 ± 9.492
15 Days, Percent Change from Baseline-18.06 ± 11.418-1.75 ± 7.581

Adverse events

Collected over 15 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phentolamine Ophthalmic Solution 0.75%0/71 (0%)0/71 (0%)23/71 (32.4%)
Phentolamine Ophthalmic Solution Vehicle0/73 (0%)0/73 (0%)2/73 (2.7%)
Most frequent other events
Most frequent other events
EventPhentolamine Ophthalmic Solution 0.75%Phentolamine Ophthalmic Solution Vehicle
Instillation site painGeneral disorders9/710/73
DysgeusiaNervous system disorders8/710/73
Conjunctival HyperaemiaEye disorders6/712/73
Instillation site erythemaGeneral disorders6/710/73

Baseline characteristics

Age, Continuous
Age, Continuous(years)Phentolamine Ophthalmic Solution 0.75%Phentolamine Ophthalmic Solution VehicleTotal
Mean47 ± 14.1445.4 ± 14.4046.2 ± 14.24
Sex: Female, Male
Sex: Female, Male(Participants)Phentolamine Ophthalmic Solution 0.75%Phentolamine Ophthalmic Solution VehicleTotal
Female6159120
Male91423
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phentolamine Ophthalmic Solution 0.75%Phentolamine Ophthalmic Solution VehicleTotal
American Indian or Alaska Native101
Asian033
Native Hawaiian or Other Pacific Islander000
Black or African American358
White6664130
More than one race000
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(Participants)Phentolamine Ophthalmic Solution 0.75%Phentolamine Ophthalmic Solution VehicleTotal
United States7073143
08

Study locations

17 sites
  • Clinical Site 6
    Newport Beach, California 92663, United States
  • Clinical Site 1
    Petaluma, California 94954, United States
  • Clinical Site 3
    Jacksonville, Florida 32204, United States
  • Clinical Site 18
    Jacksonville, Florida 32256, United States
  • Clinical Site 13
    Pittsburg, Kansas 66762, United States
  • Clinical Site 20
    Edgewood, Kentucky 41017, United States
  • Clinical Site 14
    Louisville, Kentucky 41008, United States
  • Clinical Site 10
    Palisades Park, New Jersey 07650, United States
  • Clinical Site 8
    Pennington, New Jersey 08534, United States
  • Clinical Site 4
    Elizabeth City, North Carolina 27909, United States
  • Clinical Site 22
    High Point, North Carolina 27262, United States
  • Clinical Site 9
    High Point, North Carolina 27262, United States
  • Clinical Site 2
    Fargo, North Dakota 58103, United States
  • Clinical Test 15
    Warwick, Rhode Island 57108, United States
  • Clinical Site 11
    Memphis, Tennessee 38119, United States
  • Clinical Site 5
    San Antonio, Texas 78240, United States
  • Clinical Site 19
    Ogden, Utah 84403, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in May 2022, 16 months.

Results were first posted in Aug 2023, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2020
First posted
Nov 20, 2020
StartActual
Dec 30, 2020
Primary completionActual
May 19, 2022
CompletionActual
May 19, 2022
Results first posted
Aug 9, 2023
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sponsor
Ocuphire Pharma, Inc.→Opus Genetics, Inc
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Sponsor Ocuphire Pharma, Inc.→Opus Genetics, Inc
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04638660
Lead sponsor
Opus Genetics, Inc
Responsible party
Sponsor
First posted
Nov 20, 2020
Start date
Dec 30, 2020
Primary completion
May 19, 2022
Completion
May 19, 2022
Results posted
Aug 9, 2023
Last update
Oct 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Phentolamine

Start the discussion